Christopher Hocevar - Amer Renal Independent Director
Insider
Christopher Hocevar is Independent Director of Amer Renal Assoc since 2020.
| Age | 45 |
| Tenure | 4 years |
| Phone | 978 922-3080 |
| Web | www.americanrenal.com |
Amer Renal Management Efficiency
The company has Return on Asset of 4.35 % which means that on every $100 spent on assets, it made $4.35 of profit. This is considered to be average in the sector. In the same way, it shows a return on shareholders' equity (ROE) of 17.51 %, implying that it generated $17.51 on every 100 dollars invested. Amer Renal's management efficiency ratios could be used to measure how well Amer Renal manages its routine affairs as well as how well it operates its assets and liabilities.Amer Renal Assoc has 724.51 M in debt with debt to equity (D/E) ratio of 3.94, meaning that the company heavily relies on borrowing funds for operations. Amer Renal Assoc has a current ratio of 1.03, demonstrating that it is in a questionable position to pay out its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Amer to invest in growth at high rates of return.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Arkady Tachman | Supercom | N/A | |
| Arnon Zilberman | Supercom | N/A | |
| Gil Alfi | Supercom | 45 | |
| Meir Vazana | Supercom | 52 | |
| Kyle McMillan | Plexus Corp | N/A | |
| Johne Albanese | Hooker Furniture | N/A | |
| Zvi Mitlanski | Supercom | N/A | |
| C Lo | NETGEAR | 67 | |
| Jamie Crouse | Plexus Corp | N/A | |
| Mary Kipp | Boston Properties | 51 | |
| Barak Trabelsi | Supercom | 38 | |
| Anne Smith | Hooker Furniture | 62 | |
| Gregory Pelton | Iridium Communications | N/A | |
| Talia Ozery | Supercom | N/A | |
| Eric Kevorkian | Boston Properties | 52 | |
| Suzanne McBride | Iridium Communications | 55 | |
| Heidi Cormack | NETGEAR | 49 | |
| Billy Gurevich | Supercom | 69 | |
| Manjula Sriram | Iridium Communications | N/A | |
Management Performance
| Return On Equity | 17.51 | |||
| Return On Asset | 4.35 |
Amer Renal Assoc Leadership Team
Elected by the shareholders, the Amer Renal's board of directors comprises two types of representatives: Amer Renal inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amer. The board's role is to monitor Amer Renal's management team and ensure that shareholders' interests are well served. Amer Renal's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amer Renal's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Syed Kamal, President, Co-Founder, Director | ||
| Thomas Erickson, Independent Director | ||
| Jared Hendricks, Independent Director | ||
| John Jureller, Independent Director | ||
| Robert Fish, Independent Director | ||
| Joseph Carlucci, Chairman of the Board, Chief Executive Officer, Co-Founder | ||
| Michael Boxer, Independent Director | ||
| Jeremy Gelber, Independent Director | ||
| Susanne Clark, Independent Director | ||
| Don Williamson, Chief Operating Officer, Executive Vice President | ||
| Christopher Hocevar, Independent Director | ||
| Mark Herbers, Interim Chief Financial Officer, Interim Chief Accounting Officer |
Amer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amer Renal a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 17.51 | |||
| Return On Asset | 4.35 | |||
| Profit Margin | (1.11) % | |||
| Operating Margin | 9.73 % | |||
| Current Valuation | 1.26 B | |||
| Shares Outstanding | 34.54 M | |||
| Shares Owned By Insiders | 9.15 % | |||
| Shares Owned By Institutions | 80.77 % | |||
| Number Of Shares Shorted | 608.63 K | |||
| Price To Earning | 144.04 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in Amer Stock
If you are still planning to invest in Amer Renal Assoc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Amer Renal's history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |